# Bristol-Myers Squibb Company (BMY) — Q3-2021 Earnings Results

**Report date:** 2021-10-27 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q3-2021

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Down 3.0%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.00 | N/A | +4.82% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism about their product pipeline and future prospects. However, they did not provide specific guidance for the upcoming quarters.

**Key quotes:**

> Management highlighted the strength of their pipeline despite not providing specific guidance.

> They acknowledged ongoing challenges in the market but expressed confidence in future growth.

### Guidance Changes

No guidance data is available for this quarter.

### What It Means

Bristol Myers Squibb's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 3.0%. This decline may reflect investor concerns about the lack of revenue details and future guidance, which could lead to uncertainty in the stock's performance moving forward.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q3-2021_